PAI-1 augments mucosal damage in colitis-Reference-Cited by-同舟云学术

PAI-1 augments mucosal damage in colitis

Published:2019-03-06 Issue:482 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kaiko Gerard E.¹²³^ORCID,Chen Feidi¹,Lai Chin-Wen¹,Chiang I-Ling¹,Perrigoue Jacqueline⁴^ORCID,Stojmirović Aleksandar⁴^ORCID,Li Katherine⁴^ORCID,Muegge Brian D.¹^ORCID,Jain Umang¹,VanDussen Kelli L.¹⁵^ORCID,Goggins Bridie J.²³^ORCID,Keely Simon²³,Weaver Jessica²³^ORCID,Foster Paul S.²³^ORCID,Lawrence Daniel A.⁶^ORCID,Liu Ta-Chiang¹,Stappenbeck Thaddeus S.¹^ORCID

Affiliation:

1. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.

2. School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, NSW 2308, Australia.

3. Hunter Medical Research Institute, New Lambton Heights, NSW 2305, Australia

4. Janssen Research & Development LLC, Spring House, PA 19002, USA.

5. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of Cincinnati College of Medicine and the Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA.

6. Departments of Pathology and Internal Medicine, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Abstract

SERPINE1/PAI-1 is elevated in the colon tissue of the most difficult-to-treat patients with IBD and leads to worsening of experimental colitis.

Funder

National Institutes of Health

Janssen Research and Development

NHMRC Australia

Crohn’s & Colitis Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference79 articles.